Feasibility and effectiveness of second-line chemotherapy with mitomycin C in patients with advanced penile cancer
BackgroundTriple-drug cisplatin- and taxane-based chemotherapy is the standard treatment for metastatic penile squamous cell cancer (PeSCC), with a moderate response rate of 30% to 38%. Relapse after first-line chemotherapy has a poor prognosis and there is no established second-line treatment. Mito...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-01-01
|
Series: | Frontiers in Urology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fruro.2023.1198980/full |